ZIG
EGRX

Zullo Investment Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Zullo Investment Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$2.92K – 747
2022
Q4 		$2.92K Hold
100
– – ﹤0.01% 651
2022
Q3 		$3K Hold
100
– – ﹤0.01% 677
2022
Q2 		$4K Hold
100
– – ﹤0.01% 667
2022
Q1 		$5K Hold
100
– – ﹤0.01% 671
2021
Q4 		$5K Buy
+100
New +$5.18K ﹤0.01% 674

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Zullo Investment Group's EGRX Position: Q1 2023 in Review

Zullo Investment Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2023, closing a stake of 100 shares — an estimated $2.92K sold.

Zullo Investment Group first reported a position in EGRX in Q4 2021 and held it in 5 quarters. The position peaked at $5K in Q1 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q1 2023.

  • Zullo Investment Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Zullo Investment Group sold 100 Eagle Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.92K.
  • Zullo Investment Group first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2021 and held it in 5 quarters.
  • Zullo Investment Group's Eagle Pharmaceuticals, Inc. position peaked at $5K in Q1 2022.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2023.

Based on Zullo Investment Group's 13F filing for Q1 2023, filed 25 Apr 2023.